Eiger BioPharmaceuticals, Inc.
EIGR
Clasificación en acciones
#36459
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Precio por acción
$1.73
Última sincronización: 2025-06-17
Capitalización bursátil
$2.55M
Cambio (1 día)
-0.29%
Cambio (1 año)
-79.71%
País
US
Comercio Eiger BioPharmaceuticals, Inc. (EIGR)
Categoría
Healthcare
Ratio P/S de Eiger BioPharmaceuticals, Inc. (EIGR)
Ratio P/S al October 2026 TTM: 0.80
Según los informes financieros más recientes y el precio de las acciones de Eiger BioPharmaceuticals, Inc., el ratio P/S actual (TTM) es 0.80. Al final de 2022, el ratio P/S era 3.64.
Historial del ratio P/S de Eiger BioPharmaceuticals, Inc. desde 2016 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.80 | 20.91% |
| 2023 | 0.66 | -81.89% |
| 2022 | 3.64 | -74.89% |
| 2021 | 14.51 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | 1,155.90% |
US
|
|
| 40.55 | 4,981.55% |
US
|
|
| 3.96 | 396.38% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 1,171.47% |
NL
|
